Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Receivables (2016 - 2025)

Amicus Therapeutics' Change in Receivables history spans 10 years, with the latest figure at $614000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 94.09% year-over-year to $614000.0, compared with a TTM value of $5.9 million through Dec 2025, down 69.92%, and an annual FY2025 reading of $5.9 million, down 69.92% over the prior year.
  • Change in Receivables for Q4 2025 was $614000.0 at Amicus Therapeutics, down from $8.1 million in the prior quarter.
  • The five-year high for Change in Receivables was $12.5 million in Q2 2025, with the low at -$15.3 million in Q1 2025.
  • Average Change in Receivables over 5 years is $3.5 million, with a median of $3.3 million recorded in 2021.
  • Year-over-year, Change in Receivables skyrocketed 610.07% in 2021 and then crashed 799.12% in 2024.
  • Tracing FOLD's Change in Receivables over 5 years: stood at $1.8 million in 2021, then skyrocketed by 445.07% to $9.9 million in 2022, then grew by 16.05% to $11.5 million in 2023, then fell by 9.57% to $10.4 million in 2024, then plummeted by 94.09% to $614000.0 in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Change in Receivables are $614000.0 (Q4 2025), $8.1 million (Q3 2025), and $12.5 million (Q2 2025).